An official website of the United States government
Maximize the translational potential of genetics research by ensuring rapid and broad sharing of large-scale genetic/genomic data, similar to the open science, data sharing model of the AMP AD program and by supporting programs focused on:
- Understanding the mechanisms by which genetic variants (including ApoE) discovered through GWAS and sequencing studies influence AD risk
- Integrating genomic data with other multi-omics data from brain, peripheral tissues, and iPSC cellular models from well-phenotyped cohorts
- Establishing the gene-basis and directionality for genetic variant association so gene networks can be annotated with causality as tools for drug discovery.
2024 PAR-14-070: Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01) PAR-18-889: Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01) PAR-16-406: Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project (U01) RFA-AG-16-001: NIA Coordinating Center for Genetics and Genomics of Alzheimer's Disease (U54) RFA-AG-16-002: Alzheimer's Disease Sequencing Project (ADSP) Replication Phase Analysis Studies (U01) PAR-17-214: Limited Competition: Analysis of Data from NIA's Alzheimer's Disease Sequencing Project Follow-Up Study (U01) RFA-AG-17-010: From Association to Function in the Alzheimer’s Disease Post-Genomics Era (R01) RFA-AG-18-026: From Association to Function in the Alzheimer’s Disease Post-Genomics Era (R01) RFA-AG-17-053: Human Cell Biology of Alzheimer's Disease Genetic Variants (R01) PAR-18-516: Human Cell Biology of Alzheimer's Disease Genetic Variants (R01) PAR-18-596: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01) NOT-AG-18-001 (#4): Genetic Underpinnings of Endosomal Trafficking as a Pathological Hub in AD/ADRD RFA-AG-18-013: Continuation of the AMP AD Target Discovery and Preclinical Validation Consortium (U01) RFA-AG-18-014: Limited Competition: Data Coordinating Center for the Accelerating Medicines Partnership Target Discovery and Preclinical Validation Consortium AMP AD DCC (U24) PAR-18-889: Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01 Clinical Trial Not Allowed) (Reissue of PAR-14-070) PAR-19-269: Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed) RFA-AG-21-006: Alzheimer’s Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed) NOT-AG-24-029: Notice of Special Interest (NOSI): Genetic Underpinnings of Endosomal Trafficking as a Pathological Hub in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) NOT-AG-24-039: Notice of Special Interest (NOSI): Human Cell Biology of Alzheimer's Disease Genetic Variants RFA-HG-25-007: Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed) 2.G Achieved Maximize the translational potential of genetics research by ensuring rapid and broad sharing of large-scale genetic/genomic data... DN 2018 AD Summit: 1B, 1C and 3A Blog: Symposium celebrates open science, launches new data platform Blog: Open the portal door to Alzheimer's Big Data Blog: NIAGADS! We have data! News: Gene expression signatures of Alzheimer's disease Workshop: Alzheimer’s Disease Genetics Global Symposium Workshop: Alzheimer’s Disease Genetics Global Symposium Agenda Blog: Working from home? Check out new genetics data for Alzheimer’s disease research! NIA blog: Accelerating genetic analysis of Alzheimer’s disease Study maps out genomic regions that may control levels of proteins linked to neurological disorders NIH scientists try a new twist on using ‘personalized’ stem cells for studying dementia Genetic risk factors that underlie depression may also drive Alzheimer’s disease Large-scale study of brain proteins uncovers new clues to Alzheimer’s disease Workshop: APOE Genetics as a Major Determinant of Alzheimer’s Disease Pathobiology Research on Disease Mechanisms AMP AD Target Discovery and Preclinical Validation Project Agora: AMP AD’s Web-based Interactive Platform NIA Alzheimer's Disease Genetics Portfolio Alzheimer’s Disease Sequencing Project (ADSP) NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) Functional genomic studies in diverse populations to characterize risk loci for Alzheimer Disease Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions Identifying Protective Genetic Variants for APOE4 Center for Alzheimer's and Related Dementias (CARD): iPSC Neurodegenerative Diseases Initiative Long-read DNA sequencing of Alzheimers Disease and Related Dementias cases Multi-omic functional assessment of novel AD variants using high-throughput and single-cell technologies Projects funded under RFA-AG-21-006
- Launch an open science research program focused on generating knowledge on the mechanisms by which genetic variants influence AD risk and the directionality for genetic variation association. Develop gene networks that are annotated with causality as open source analytical tools for drug discovery.
Summary of Key Accomplishments
NIA is advancing the achievement of this milestone is in two major ways: by investing in genetics research aimed at resolving the complex genetics of AD, and by launching targeted initiatives aimed at understanding the mechanisms by which genetic variants influence AD risk and resilience. These programs support cutting-edge molecular and cellular biology research, as well as artificial intelligence methods. The Alzheimer’s Disease Sequencing Project Functional Genomics Consortium supports a team-science strategy and applies genome-wide approaches to discover and characterize functional genomic and epigenomic elements and elucidate and validate their roles and the mechanisms of action underpinning Alzheimer’s disease and related dementias (AD/ADRD).
The key accomplishments summary is current as of July 2022.